About ODIN Biotech Partners

About company

ODIN Biotech Partners, LLC is a development-stage biotechnology company focused on developing novel peptide therapeutics for diseases of the retina. ODIN’s lead product, C16Y, is currently in preclinical development for the treatment of wet age-related macular degeneration (AMD). ODIN expects to begin clinical studies of C16Y in early 2016. It was founded in 2014 and is based in Dallas, Texas, United States.